TMPRSS2 and COVID-19: A deep learning-based drug–target interaction model predicts that certain anti-hepatitis C virus (HCV) medicines, like ombitasvir, daclatasvir, and paritaprevir, have a substantial affinity for TMPRSS2 and could potentially be repurposed for COVID-19 treatment [77].